Skip to main content

Table 1 Clinical characteristics of the populations with PBMCs enrolled in the study

From: IFI16 is involved in HBV-associated acute-on-chronic liver failure inflammation

group

NC

CHB

HBV-ACLF

case

16

31

13

sex(M/F)

12/4

25/6

12/1

age(years)

29.5(26-63)

36(21-61)

44(37-67)

ALT(U/L)

21.5(11-34)

50(11-217)

90(46-245)

AST(U/L)

22(12-34)

46(21-222)

117(58-158)

Tbil(umol/L)

ND

12.6(4.0-119.9)

473.8(51.9-720)

INR

ND

1.04(0.88-1.23)

2.87(2.01-4.68)

PTA(%)

ND

94(72-128)

26(16-39)

Log10 (HBV DNA)

ND

5.17(1.30-8.23)

3.25(1.51-8.19)

HBsAg-positive

0

31

13

HBsAb-positive

16

0

0

HBeAg-positive

0

13

3

HBeAb-positive

0

18

10

HBcA-bpositive

0

31

13

MELD score

ND

ND

28.2±1.22

  1. Data are shown as median and range
  2. ACLF, acute on chronic liver failure; CHB, chronic hepatitis B; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Tbil, total bilirubin;HBcAb, hepatitis B c antibody; HBeAb, hepatitis B e antibody; HBeAg, hepatitis B e antigen; HBsAb, hepatitis B s antibody; HBsAg,hepatitis B s antigen; HBV, hepatitis B virus; ND, not determined; NC,normal control; PTA, prothrombin time activity; MELD Model for end-stage liver disease